CLEAR CELL RENAL CELL CARCINOMA

This study is testing whether adding an immunotherapy drug to a new targeted therapy works better than the targeted therapy alone for advanced kidney cancer. It's for patients whose cancer has returned or spread after receiving standard post-surgery treatment. Participants will b…

This study is testing a new combination of three drugs for people with advanced kidney cancer who haven't had prior treatment. The goal is to see if the combination can control the cancer and is safe for patients. About 100 participants will receive a targeted radiation drug plus…

This study is testing whether adding a second immunotherapy drug (fianlimab) to a standard one (cemiplimab) works better to control cancer after precise radiation treatment. It involves 72 adults with clear cell kidney cancer that has spread to only a few other sites in the body.…

This study is testing whether a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted drug (lenvatinib) can shrink kidney tumors before surgery. The goal is to make a kidney-sparing operation possible and safer for 25 patients whose tumors are curr…

This study is testing if adding a new drug called SLC-3010 to an existing cancer drug (axitinib) works better than using axitinib alone. It is for adults with a specific type of advanced kidney cancer that has worsened after their first treatment. The main goal is to see if the c…

This study is testing a new medicine called PF-08634404 for adults with advanced kidney cancer that has spread. Researchers want to see if the medicine is safe and effective when given alone or with other cancer drugs. The study is recruiting 224 adults who haven't received any t…

This is the first study in people testing a new cancer drug called MGC026. It aims to find a safe dose and see if the drug can help shrink tumors in adults with advanced solid tumors that have not responded to other treatments. The study will also check how the drug moves through…

This is the first study in people to test a new drug called AB521 (casdatifan). The main goal is to find safe doses and see how the body processes the drug. It will be tested alone and in combinations for people with advanced kidney cancer and other solid tumors that have not res…

This early-stage trial is testing a new cancer drug called NN3201 for the first time in people. The study aims to find a safe dose and see how well the drug works against several advanced solid tumors that have a specific protein called c-Kit. Researchers will enroll 67 adults wi…

This is the first study in people testing a new oral drug called NEO-811 for advanced kidney cancer that has spread or cannot be removed by surgery. The main goals are to find a safe dose and see how the body handles the drug. It is for patients whose cancer has continued to grow…

This large, late-stage trial is testing if a two-drug combination works better than the current standard single drug to prevent kidney cancer from returning after surgery. It will enroll over 1,000 patients whose cancer is at high risk of coming back. The goal is to see if adding…

This early-stage study is testing a new drug called XmAb819 in people with advanced kidney cancer that has returned or stopped responding to standard treatments. The main goal is to find safe dose levels and check for side effects when the drug is given through an IV or injection…

This study is testing whether giving one or two drugs before surgery can better control a type of kidney cancer called clear cell renal cell carcinoma. It will compare belzutifan alone, pembrolizumab alone, or the two drugs together in about 10 patients with locally advanced canc…

This study is testing a new type of PET/CT scan to see if it can accurately detect a specific protein (HIF2α) inside kidney cancer tumors. It is for research only and will not treat the cancer. The goal is to see if the scan results match what is found in actual tumor tissue samp…